Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
NIS | Ann: High-Grade Copper-Gold Results at Mt Isa North | 15:33 | 15 | 3.5K | |||
|
|||||||
NIS | Ann: Annual Report to shareholders | 01/10/24 | 4 | 942 | |||
|
|||||||
NIS | Ann: Appendix 4G & Corporate Governance Statement | 30/09/24 | 0 | 141 | |||
|
|||||||
NIS | NIS chart | 27/09/24 | 679 | 164K | |||
|
|||||||
NIS | Ann: Change in substantial holding from MM8 | 24/09/24 | 31 | 5.3K | |||
|
|||||||
NIS | Ann: Update - Proposed issue of securities - NIS | 19/09/24 | 0 | 186 | |||
|
|||||||
NIS | Ann: Non Renounceable Rights Issue Extension of Offer Period | 19/09/24 | 0 | 217 | |||
|
|||||||
NIS | Ann: NIS Acquisition Investor Presentation August 2024 | 18/09/24 | 2 | 839 | |||
|
See All Discussions
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |